Inevica

Ivabradine, the active ingredient in Inevica, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Inevica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable logistics for global patients.

Ivabradine acts on the cardiac If current to manage conditions characterized by elevated heart rate.

Chronic stable angina pectoris: improves exercise tolerance and reduces frequency of angina episodes. Heart failure with reduced ejection fraction (HFrEF): lowers resting heart rate, alleviates symptoms and may decrease hospitalisation risk. Ischemic heart disease: helps control heart rate when beta‑blockers are insufficient or not tolerated.

Common Side Effects: - Bradycardia: unusually slow heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other significant arrhythmias. - Severe hypotension. - Symptomatic heart block. - Worsening heart failure. - Allergic reactions such as rash, angioedema or anaphylaxis.

Ivabradine should be used with careful clinical assessment and monitoring.

Cardiac monitoring: obtain baseline heart rate and ECG before initiation. Contraindicated in severe hypotension: avoid use when systolic BP <90 mmHg. Avoid in patients with sick sinus syndrome or atrioventricular block. Caution in hepatic impairment: dose adjustment may be required. Avoid concomitant strong CYP3A4 inhibitors: may increase drug exposure. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Ivabradine may interact with several medicines that affect heart rate or metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Concomitant bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction. - Other If channel inhibitors: additive effect on heart rate.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine efficacy. - Verapamil or diltiazem: moderate increase in ivabradine concentrations. - Alcohol: can enhance bradycardic effect, especially in susceptible patients.